Phase 2
Completed N=50
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
Source: ClinicalTrials.gov NCT00973102 ↗Enrolled (actual)
50
Serious AEs
25.0%
Results posted
Mar 2020
Primary outcomePrimary: Survival — 16; 21 participants — p=.252
Summary
Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Survival |
16; 21 | .252 |
| SECONDARY Acute Respiratory Distress Syndrome (ARDS) Free Survival |
3.00; 3.33 | .895 |
Eligibility Criteria
Inclusion Criteria
- Age≥ 18 yrs or 120 minutes after the traumatic event
- Time of injury is unknown
- Known indication for IV estrogen
- Known contraindication for estrogen
- Estimated age 50 years
- Cardiopulmonary Resuscitation (CPR) prior to randomization
- Known incarceration
- Severe hypothermia (suspected T 20%
- Isolated penetrating injury to the head
- Known inclusion in another interventional trial related to this traumatic event prior to randomization
- Known legal do not resuscitate (DNR) orders in place prior to randomization
- Recognized spinal cord injury prior to study drug administration
Data sourced from ClinicalTrials.gov (NCT00973102). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.